The briefing
TIGRa, a gene activation platform about half the size of CRISPRa, is reported to markedly improve therapeutic deliverability in vivo. The smaller footprint could ease vector packaging constraints and broaden gene activation applications.
Original headline
Smaller Gene Activation Platform TIGRa Improves In Vivo Deliverability